Tonix Pharmaceuticals Holding Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$34.2Mnext fiscal year
FY EPS (est.)
-$10.10next fiscal year
Monitoring Framework
Key Performance Indicators
TONMYA Net Sales Quarterly3.7MTarget: Continued commercial expansion and payer coverage growth
Total Cash and Cash Equivalents Quarterly185.5MTarget: Maintain sufficient runway into early Q2 2027
Unique Prescribers for TONMYA Quarterly2.6KTarget: Expand physician adoption across the U.S.
Watch Items
- TNX-102 SL Phase 2 HORIZON Study in Major Depressive Disorder (MDD)Trigger: Initiation of patient enrollmentAction: Monitor clinical trial progress and timeline updates
- TNX-4800 Phase 2 Lyme Disease Prevention Field StudyTrigger: FDA agreement and initiation of adaptive Phase 2 field study in 1H 2027Action: Track regulatory clearances and clinical trial supply availability
- TONMYA Commercial Payer CoverageTrigger: Expansion beyond current ~52 million covered U.S. livesAction: Evaluate commercial uptake and market access milestones
Research as of 20 Jun 2026